Zheng Quan Shi Bao Wang·2025-12-09 13:43Core Insights - The completion of over $110 million in Series B financing marks a significant milestone in the company's development, with support from top global investment institutions, indicating trust in the company's R&D capabilities and long-term vision [1][2] Group 1: Financing Details - The Series B financing was led by a well-known industry institution, with participation from a sovereign wealth fund, China National Pharmaceutical Group, and several venture capital firms [1] - Existing shareholders, including Hillhouse Capital, Qiming Venture Partners, and others, continued to support the financing round [1] Group 2: Company Development and Pipeline - Since its establishment in 2021, the company has focused on developing innovative RNAi therapies targeting liver and extrahepatic tissues, with a diverse product pipeline covering autoimmune diseases, cardiovascular diseases, metabolic diseases, and obesity [1] - Several products in the pipeline have already entered clinical stages, and the successful financing will enhance clinical development and global expansion efforts [1] Group 3: Strategic Partnerships - The company recently announced a global R&D collaboration and licensing agreement with Eli Lilly, aimed at developing RNAi candidates for metabolic diseases based on the company's proprietary LEAD platform [2] - The agreement includes an upfront payment and equity investment, with potential milestone payments of up to $1.2 billion and tiered royalties on commercial sales [2]